[Hub]/) : Traits : Lung cancer (father) :

chr15:78,032,707-79,573,404

Best TWAS P=1.44e-16 · Best GWAS P=3.97e-15 conditioned to 0.12

Associated models

# Study Tissue Gene h2 eQTL R2 model # weights model R2 model R2 P eQTL GWAS Z TWAS Z TWAS P Top SNP corr PP3 PP4 joint
1 GTEx Liver PSMA4 0.18 0.14 lasso 1 0.11 6.5e-04 7.9 7.9 4.0e-15 1.00 0.01 0.97 FALSE
2 GTEx Testis CHRNA5 0.16 0.07 enet 11 0.11 1.4e-05 7.9 6.7 2.3e-11 0.86 0.01 0.99 FALSE
3 YFS Blood IREB2 0.18 0.20 enet 28 0.24 4.0e-78 7.2 -6.5 8.6e-11 -0.74 0.22 0.78 FALSE
4 YFS Blood PSMA4 0.08 0.08 lasso 10 0.11 8.3e-35 7.7 8.3 1.4e-16 0.85 0.01 0.99 TRUE
5 The Cancer Genome Atlas Esophageal Carcinoma CHRNA3 0.24 0.15 enet 5 0.16 6.5e-06 7.9 -6.8 8.9e-12 -0.94 0.00 1.00 FALSE
6 The Cancer Genome Atlas Esophageal Carcinoma CHRNA5 0.17 0.15 lasso 4 0.14 3.1e-05 7.9 -7.9 3.3e-15 -0.98 0.00 0.98 FALSE
7 The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma ADAMTS7 0.08 0.07 lasso 3 0.06 4.2e-04 5.5 5.5 4.9e-08 0.62 0.02 0.79 FALSE
8 The Cancer Genome Atlas Brain Lower Grade Glioma ADAMTS7 0.08 0.07 lasso 3 0.07 4.9e-08 5.4 5.5 3.7e-08 0.62 0.03 0.97 FALSE
9 The Cancer Genome Atlas Liver Hepatocellular Carcinoma PSMA4 0.08 0.02 blup 40 0.03 1.1e-02 -4.6 -6.2 6.1e-10 -0.54 0.05 0.21 FALSE
10 The Cancer Genome Atlas Lung Adenocarcinoma CHRNA5 0.02 0.01 blup 50 0.02 2.6e-03 -2.7 -5.5 4.9e-08 -0.86 0.02 0.75 FALSE
11 The Cancer Genome Atlas Lung Squamous Cell Carcinoma PSMA4 0.03 0.02 blup 40 0.02 3.1e-03 -2.7 5.5 4.8e-08 0.81 0.02 0.50 FALSE
12 The Cancer Genome Atlas Pheochromocytoma and Paraganglioma CHRNA5 0.15 0.07 blup 50 0.09 2.5e-04 -5.9 -7.4 1.5e-13 -0.66 0.20 0.48 FALSE
13 The Cancer Genome Atlas Prostate Adenocarcinoma CHRNA3 0.04 0.04 blup 44 0.06 1.4e-06 7.2 -5.9 3.5e-09 -0.85 0.02 0.98 FALSE
14 The Cancer Genome Atlas Prostate Adenocarcinoma CHRNA5 0.04 0.01 enet 10 0.03 6.0e-04 7.9 -6.3 2.7e-10 -0.78 0.01 0.85 FALSE
15 The Cancer Genome Atlas Stomach Adenocarcinoma CHRNA3 0.05 0.02 blup 44 0.02 7.6e-03 7.9 -6.0 2.1e-09 -0.90 0.00 0.98 FALSE